Topic: acute myeloid leukemia (AML)
Seven of the 13 newly diagnosed AML patients with a certain biomarker had full complete responses after receiving the RARα agonist and Vidaza.
The series B will equip Arcellx to move an anti-BCMA candidate into the clinic in multiple myeloma while advacing other assets.
Patients who took CC-486 lived longer than their peers on placebo, setting Celgene up to file for approval of the drug in the first half of next year.
Just days after Daiichi’s Xospata challenger scored approval in Japan for a form of acute myeloid leukemia, the FDA declined to clear the drug in the U.S.
The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.
Daiichi Sankyo went one for two in an FDA advisory committee doubleheader Tuesday, with its prospective leukemia treatment getting struck out.
The FDA has questioned the reliability of the phase 3 results Daiichi Sankyo hopes will win it approval for quizartinib in acute myeloid leukemia.
Daiichi’s PDUFA date for its FLT3 inhibitor has been pushed back to late August, as the FDA wants more time to review data from the Japanese pharma.
Swedish p53 cancer biotech Aprea Therapeutics has nabbed former Agios senior medical director Eyal Attar as its senior vice president and chief medical officer.
The FDA placed a partial clinical hold on a bispecific antibody in development for acute myeloid leukemia following reports of two patient deaths.